Key Takeaways Sarepta reported a Q4 loss of $3.58 per share as Elevidys sales plunged over 71% year over year.SRPT revenues fell 33% to $442.9M, but still beat estimates on higher collaboration income.Sarepta guided 2026 net product revenues of $1.2B-$1.4B and targets $800M-$900M in expenses.Sarepta Therapeutics, Inc. (SRPT) reported a fourth-quarter 2025 adjusted loss of $3.58 per share, wider than the Zacks Consensus Estimate of a loss of 71 cents. This higher-than-anticipated loss was attributed to an in ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) demonstrates a strong Return on Invested Capital (ROIC) of 20.84% compared to its Weighted Average Cost of Capital (WACC) of 9.83%, indicating efficient capital utilization.ACADIA Pharmaceuticals leads with the highest ROIC to WACC ratio among peers, suggesting superior efficiency and growth potential.Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a biopharmaceutical company that focuses on developing medicines that treat intractable diseases by silencing the ...

Core Insights - Arrowhead Pharmaceuticals focuses on developing medicines for intractable diseases by silencing the genes that cause them, operating in a competitive biopharmaceutical industry alongside peers like Alnylam Pharmaceuticals, Amicus Therapeutics, ACADIA Pharmaceuticals, and Axsome Therapeutics [1] Financial Metrics Comparison - Arrowhead Pharmaceuticals has a Return on Invested Capital (ROIC) of 20.84%, significantly higher than its Weighted Average Cost of Capital (WACC) of 9.86%, resulting in a ROIC to WACC ratio of 2.11, indicating efficient capital utilization and potential for growth [2] - Alnylam Pharmaceuticals shows a negative ROIC of -10.44% against a WACC of 5.30%, leading to a ROIC to WACC ratio of -1.97, highlighting inefficiencies in capital utilization [3] - Amicus Therapeutics also reports a negative ROIC of -13.65% with a WACC of 6.20%, resulting in a ROIC to WACC ratio of -2.20, indicating challenges in generating returns above its cost of capital [3] - ACADIA Pharmaceuticals stands out with a ROIC of 23.32% and a WACC of 6.74%, yielding a ROIC to WACC ratio of 3.46, suggesting strong capital efficiency and growth potential [4] - Axsome Therapeutics has a notably negative ROIC of -55.37%, far below its WACC of 5.53%, resulting in a ROIC to WACC ratio of -10.02, indicating significant challenges in capital utilization [5][6]

Core Insights - The Vanguard Small-Cap ETF (VB) and the State Street SPDR Portfolio S&P 600 Small Cap ETF (SPSM) are both low-cost options for investors interested in U.S. small-cap stocks, but they differ in portfolio composition and performance nuances [1] Cost & Size - Both VB and SPSM have an expense ratio of 0.03% [2][3] - As of February 12, 2026, VB has a 1-year return of 10.65% compared to SPSM's 10.28% [2] - SPSM offers a higher dividend yield of 1.53% versus VB's 1.27% [2] - VB has significantly larger assets under management (AUM) at $169 billion compared to SPSM's $14 billion [2] Performance & Risk Comparison - Over the past five years, VB experienced a maximum drawdown of -28.16%, while SPSM had a slightly lower drawdown of -27.95% [4] - An investment of $1,000 in VB would have grown to $1,260 over five years, while the same investment in SPSM would have grown to $1,216 [4] Portfolio Composition - SPSM tracks the S&P SmallCap 600 Index and includes 607 stocks, with top sectors being financial services (17%), industrials (16%), and consumer cyclical (15%) [5] - VB holds a broader portfolio of 1,324 stocks, with a focus on industrials (19%), technology (17%), and financial services (13%) [6] Investment Implications - VB's greater diversification, with more than twice the number of stocks as SPSM, may help limit risk associated with small-cap stocks [7] - VB's heavier allocation to technology (17% vs. 13% for SPSM) may lead to higher volatility but also greater long-term returns [8] - Both funds have shown similar total returns over 12 months and five years, but VB has slightly outperformed SPSM in both periods [9]

Core Insights - The small nucleic acid sector is experiencing a significant commercialization phase, driven by technological breakthroughs and successful clinical data releases in the weight loss domain [1][3][6] - Major transactions, including a billion-level acquisition by China Biologic and the Hong Kong listing of Rebio, indicate that capital exit channels are now open [1][5][6] Group 1: Clinical Data Releases - Arrowhead Pharmaceuticals announced clinical data for two siRNA obesity candidates, ARO-INHBE and ARO-ALK7, showing improvements in visceral fat and total fat in obese patients with type 2 diabetes, leading to a 10.9% stock price increase [3] - Wave Life Sciences reported that its siRNA drug WVE-007 achieved a 4.0% weight reduction and a 0.9% muscle gain in a Phase I trial, resulting in a 147.3% stock price surge [4] - The clinical data from these small nucleic acid drugs suggest potential for use either alone or in combination with GLP-1 drugs to reduce fat while preserving muscle [4][7] Group 2: Business Development Transactions - In early 2026, Anlong Bio secured an international strategic cooperation agreement in the small nucleic acid drug field worth over $100 million, marking a significant breakthrough in international business development [5] - China Biologic announced a 1.2 billion RMB acquisition of Hejiya Bio, enhancing its small nucleic acid portfolio and leveraging Hejiya's unique long-acting delivery platform [5][6] - Saintin Bio has engaged in multiple business development deals, including a strategic collaboration with Genentech worth up to $15 billion for RNAi drug development [17] Group 3: Market Trends and Future Outlook - The small nucleic acid sector is increasingly recognized as a core area for innovative drug development, with expectations for more significant events in the future [2][6] - The weight loss market is identified as a potential area for major transactions, driven by the large market size and the growing recognition of clinical efficacy for small nucleic acid drugs [7][19] - Major pharmaceutical companies are actively exploring collaborations in the small nucleic acid space, particularly in conjunction with GLP-1 drugs to enhance therapeutic outcomes [18][20]

Financial Data and Key Metrics Changes - For Q1 2026, the company reported a net income of $30.8 million, translating to an income of $0.22 per share, a significant improvement from a net loss of $173.1 million or a loss of $1.39 per share in Q1 2025 [31] - Revenue for the quarter totaled $264 million, primarily driven by licensing collaborations with Sarepta and Novartis, with approximately $229 million from the Sarepta collaboration [31][32] - Total operating expenses increased to approximately $223 million from $164 million in the prior year, driven by higher R&D and SG&A expenses [33] Business Line Data and Key Metrics Changes - The company launched its first commercial product, Redemplo, approved for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS) [5][8] - Over 100 prescriptions for Redemplo have been received, with a balanced uptake across the U.S. [20] - The cardiometabolic pipeline includes ongoing studies for Zodasiran and new candidates ARO-INHBE and ARO-ALK7, with promising early results in weight loss and fat reduction [9][29] Market Data and Key Metrics Changes - The FDA approved Redemplo, marking a significant milestone for the company, with additional approvals from Health Canada and the Chinese National Medical Products Administration expected [8] - The company anticipates launching Redemplo in select EU countries and the U.K. later in 2026 [8] - The potential market for mixed hyperlipidemia, targeted by ARO-DimerPA, includes approximately 20 million people in the U.S. [11] Company Strategy and Development Direction - The company is focused on sustainable innovation and rational drug pricing, emphasizing the value offered to patients and healthcare systems [7] - Arrowhead aims to become cash flow positive and self-sustaining through multiple independent and partner launches, having completed transactions with gross proceeds of $1.33 billion [15][16] - The company is expanding its CNS portfolio with new delivery systems designed to penetrate the blood-brain barrier, targeting conditions like Alzheimer's disease [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position to build on recent achievements and highlighted the potential for significant growth in 2026 and beyond [5][37] - The company expects key events in 2026, including commercial sales progress for Redemplo and readouts from phase III studies for plozasiran [37] - Management remains optimistic about the early feedback from payers and healthcare providers regarding Redemplo [21][57] Other Important Information - The company has strengthened its balance sheet significantly, with cash and investments totaling $917 million as of December 31, 2025 [34][35] - The company is not disclosing specific sales numbers for Redemplo until they become a meaningful driver of financials [32] Q&A Session Summary Question: Can you provide a breakdown of patient categories for Redemplo? - The majority of patients are from the APOC3 naive segment, with the remaining balance split roughly 50/50 between switch patients and those transitioning from the expanded access program [41][42] Question: What are the timelines for discussions with the FDA regarding obesity treatments? - Discussions with the FDA are expected around mid-year, and an IND filing is anticipated shortly thereafter [44] Question: What level of reduction in LDL-C and triglycerides are you looking for with ARO-DimerPA? - A reduction of around 40%-50% in both LDL and triglycerides would be encouraging for advancing the asset [46][47] Question: How are you thinking about potential pricing for ARO-INHBE and ARO-ALK7? - It is too early to speculate on pricing as the company is still assessing the biology and potential efficacy of these candidates [50][51] Question: Can you discuss the pancreatitis event rates in ongoing trials? - The company is not providing additional details on event rates but acknowledges that events are being observed [53][54] Question: Has the pricing for Redemplo been discussed in relation to the SHTG market? - The focus is on ensuring coverage and access for high-risk patients, with discussions reflecting the clinical and economic value of Redemplo [56][59]

Financial Data and Key Metrics Changes - The company reported a net income of $30.8 million for Q1 2026, translating to an income of $0.22 per share, a significant improvement from a net loss of $173.1 million or a loss of $1.39 per share in Q1 2025 [31] - Revenue for the quarter totaled $264 million, primarily driven by licensing collaborations with Sarepta and Novartis, with approximately $229 million from the Sarepta collaboration [31][32] - Total operating expenses increased to approximately $223 million from $164 million in the prior year, driven by higher R&D and SG&A expenses [33] Business Line Data and Key Metrics Changes - The company launched its first commercial product, REDEMPLO, which received FDA approval on November 18, 2025, and has seen over 100 prescriptions within the first 10 weeks of launch [5][7][20] - REDEMPLO is positioned as a treatment for familial chylomicronemia syndrome (FCS), with a median triglyceride reduction of 80% from baseline observed in clinical studies [6][22] - The cardiometabolic pipeline includes ongoing studies for zodasiran in homozygous familial hypercholesterolemia and several obesity treatment candidates, with promising early data reported for ARO-INHBE [8][9][29] Market Data and Key Metrics Changes - The company anticipates launching REDEMPLO in Canada and select EU countries later in 2026, with marketing in Greater China to be handled by Sanofi [8] - The U.S. market for mixed hyperlipidemia is estimated to include approximately 20 million people, with a focus on high-risk patients for REDEMPLO [11][12] Company Strategy and Development Direction - The company is committed to sustainable innovation and rational drug pricing, emphasizing the value of medicines to patients and healthcare systems [7] - Future strategic priorities include advancing the cardiometabolic and CNS pipelines, with a focus on addressing obesity, cardiovascular disease, and neurodegenerative conditions [15][13] - The company has strengthened its balance sheet with $1.33 billion in gross proceeds from various transactions, enabling multiple program advancements [17][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position to build on recent achievements and highlighted the potential for significant growth in 2026 and beyond [5][37] - The company expects key events in 2026, including commercial sales progress for REDEMPLO and readouts from phase III studies for plozasiran, which could represent a $3 billion-$4 billion opportunity [37] Other Important Information - The company has received breakthrough therapy designation for plozasiran, expediting its development for severe hypertriglyceridemia [25] - The proprietary TRiM platform is being utilized to enhance delivery systems for CNS-targeted therapies, with ARO-MAPT and SRP-1005 as key programs [13][14] Q&A Session Summary Question: Can you provide a breakdown of patient categories for REDEMPLO? - The majority of patients are from the APOC3 naive segment, with the remainder split evenly between switch patients and those transitioning from the expanded access program [41][42] Question: What are the expectations for the obesity development path? - Discussions with the FDA are anticipated around mid-year, and not all data from cohorts are required before determining next steps [44] Question: What level of reduction in LDL-C and triglycerides is expected for ARO-DimerPA? - A reduction of around 40%-50% in both LDL and triglycerides would be encouraging for advancing the asset [47] Question: How is pricing being considered for ARO-INHBE and ARO-ALK7? - It is too early to speculate on pricing as the biology of the drug candidates is still being understood [50] Question: What are the expectations for pancreatitis event rates in ongoing trials? - Specific details on event rates are not being disclosed, but events are being observed [53] Question: How is payer feedback for REDEMPLO shaping up? - Positive feedback has been received, with discussions focused on ensuring coverage for high-risk patients [56][59]

Financial Data and Key Metrics Changes - The company reported a net income of $30.8 million for Q1 2026, translating to an income of $0.22 per share, a significant improvement from a net loss of $173.1 million or a loss of $1.39 per share in Q1 2025 [31] - Revenue for the quarter totaled $264 million, primarily driven by licensing collaborations with Sarepta and Novartis, with approximately $229 million from the Sarepta collaboration [31][32] - Total operating expenses increased to approximately $223 million from $164 million in the prior year, driven by higher R&D and SG&A expenses [33] Business Line Data and Key Metrics Changes - The company launched its first commercial product, Redemplo, which received FDA approval as an adjunct to diet for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS) [4][5] - Over 100 prescriptions for Redemplo have been received, with a balanced uptake across the U.S. and a significant proportion of patients enrolling in the patient support program [6][19] - The cardiometabolic pipeline includes ongoing studies for Zodasiran and new candidates ARO-INHBE and ARO-ALK7, with promising early data reported [9][10] Market Data and Key Metrics Changes - The company anticipates launching Redemplo in Canada and select EU countries later in 2026, with Sanofi marketing it in Greater China [8] - The U.S. market for mixed hyperlipidemia is estimated to include approximately 20 million people, representing a significant opportunity for the ARO-DimerPA candidate [11] Company Strategy and Development Direction - The company is focused on sustainable innovation and rational drug pricing, emphasizing the value of medicines to patients and healthcare systems [6] - Arrowhead aims to become cash flow positive and self-sustaining from commercial sales, with a strong emphasis on expanding its cardiometabolic and CNS portfolios [15][12] - The company has strengthened its balance sheet with $1.33 billion in gross proceeds from various transactions, enabling further development and commercialization efforts [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's position to build on recent achievements and highlighted the potential for significant revenue opportunities from upcoming product launches [4][17] - The company expects key events in 2026, including commercial sales progress for Redemplo and readouts from phase III studies for plozasiran, which could represent a $3-$4 billion opportunity [38] Other Important Information - The company has received breakthrough therapy designation for plozasiran, expediting its development for severe hypertriglyceridemia [25] - Arrowhead's proprietary TRiM platform is being utilized to enhance drug delivery across various tissues, including the CNS [12] Q&A Session Summary Question: Can you provide a breakdown of patient categories for Redemplo? - The majority of patients are from the APOC3 naive segment, with the remaining balance split roughly 50/50 between switch patients and those transitioning from the expanded access program [42][43] Question: What are the expectations for the obesity programs and FDA discussions? - Discussions with the FDA are expected around mid-year, and the company does not need all data from cohorts before determining the next steps [46] Question: What level of LDL-C and triglyceride reduction is expected for ARO-DimerPA? - A reduction of around 40%-50% in LDL and triglycerides would be encouraging for advancing the asset [48][49] Question: How is pricing being considered for ARO-INHBE and ARO-ALK7? - It is too early to speculate on pricing as the company is still assessing the biology and potential efficacy of these candidates [51] Question: What are the expectations for pancreatitis event rates in ongoing trials? - The company is not providing additional details on event rates but acknowledges that events are being observed [54] Question: How is payer feedback for Redemplo shaping discussions for SHTG? - Payer discussions are focused on ensuring coverage for high-risk patients, with a strong emphasis on the clinical and economic value of Redemplo [57][60]

Financial Performance - Total revenue for the three months ended December 31, 2025, increased by $261.5 million compared to the same period in 2024, primarily driven by revenue recognition from collaboration agreements with Sarepta, Novartis, and Sanofi [176]. - The Company reported an operating income of $40.8 million for the three months ended December 31, 2025, compared to an operating loss of $161.4 million in the same period of 2024 [175]. - Net income attributable to Arrowhead for the three months ended December 31, 2025, was $30.8 million, a significant improvement from a net loss of $173.1 million in the same period of 2024 [175]. - The Company recorded $229.5 million in revenue from the Sarepta Collaboration Agreement during the three months ended December 31, 2025 [179]. - Cash flow from operating activities was $13.5 million for the three months ended December 31, 2025, primarily due to cash received from the Novartis agreement [208]. - Cash, cash equivalents, and restricted cash were $201.6 million as of December 31, 2025, down from $226.5 million as of September 30, 2025 [203]. Research and Development - Research and development expenses totaled $177.2 million for the three months ended December 31, 2025, a 29% increase from $137.0 million in the same period of 2024 [200]. - Candidate costs increased by $28.1 million, or 37%, primarily due to higher outsourced clinical trial costs and manufacturing expenses [187]. - R&D discovery costs rose by $8.9 million, or 69%, reflecting increased activity in novel therapeutic areas [188]. - The Company has a diverse clinical pipeline targeting various conditions, including severe hypertriglyceridemia, cardiovascular disease, and neurodegenerative diseases [171]. Collaborations and Agreements - The Company entered into a licensing and collaboration agreement with Novartis, receiving $200.0 million as an upfront payment [206]. - The Company earned a $200.0 million milestone payment from Sarepta Therapeutics on November 20, 2025, related to the Phase 1/2 clinical study of ARO-DM1 [172]. Clinical Developments - The FDA granted Breakthrough Therapy designation to investigational plozasiran for reducing triglyceride levels in adults with severe hypertriglyceridemia, with TG levels greater than or equal to 500 mg/dL [172]. - ARO-INHBE, in combination with tirzepatide, nearly doubled weight loss at week 16 and tripled reductions in visceral fat compared to tirzepatide alone in obese patients with type 2 diabetes [178]. - ARO-ALK7 achieved a mean reduction of -88% in adipose ALK7 mRNA at the 200 mg dose at week 8, marking a significant milestone in RNAi therapeutics [178]. Expenses and Liquidity - Total general and administrative expenses were $46.0 million for the three months ended December 31, 2025, a 71% increase from $26.9 million in the same period of 2024 [194]. - Professional, outside services, and other expenses increased by $8.8 million, or 87%, due to costs associated with the commercialization of new products [195]. - The Company expects sufficient liquidity to fund operations for at least the next twelve months [208].

Financial Performance - Arrowhead Pharmaceuticals reported revenue of $264,033,000 for the first quarter of fiscal 2026, a significant increase from $2,500,000 in the same period last year[11] - The company achieved an operating income of $40,809,000 compared to an operating loss of $161,412,000 in the prior year[11] - Net income attributable to Arrowhead Pharmaceuticals was $30,811,000, a turnaround from a net loss of $173,085,000 in the previous year[11] - Arrowhead closed two public offerings with gross proceeds totaling $930,000,000, enhancing its financial position[8] Product Development and Approvals - The company received FDA approval for REDEMPLO (plozasiran) for treating familial chylomicronemia syndrome, marking its first FDA-approved medicine[5] - Over 100 prescriptions for REDEMPLO have been received from a diverse prescriber base, indicating strong initial uptake across the U.S.[5] - Interim clinical data for ARO-INHBE showed a weight loss of -9.4% at week 16 in obese patients with type 2 diabetes, demonstrating a two-fold improvement compared to tirzepatide alone[8] - ARO-ALK7 achieved a mean reduction of -88% in ALK7 mRNA, marking a significant advancement in RNAi therapeutics[8] Strategic Partnerships - The company triggered a $200 million milestone payment from Sarepta Therapeutics for reaching enrollment targets in a clinical study[8] - Arrowhead entered a global licensing agreement with Novartis, receiving a $200 million upfront payment and potential milestone payments of up to $2 billion[9]